Biomerica (BMRA) director adds 6,250 shares in private deal
Rhea-AI Filing Summary
BIOMERICA INC (BMRA) director Eric Chin reported buying common stock in a company financing. On August 26, 2026, he purchased 6,250 shares of Biomerica common stock at $1.60 per share in a private placement by Biomerica under a Securities Purchase Agreement dated August 20, 2026. Following this transaction, he directly holds 38,750 shares of Biomerica common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 6,250 shares
Net Buy
1 txn
Insider
Chin Eric
Role
Director
Bought
6,250 shs ($10K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common stock F1 | 6,250 | $1.60 | $10K |
Holdings After Transaction:
Common stock — 38,750 shares (Direct)
Footnotes (1)
- F1. On August 26, 2026, the reporting person acquired 6,250 shares of the Issuer's common stock at a purchase price of $1.60 per share in private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026, by and among certain institutional and individual investors identified on the signature pages thereto, which included among others B. Riley Principal Capital, LLC and certain members of the Company's Board of Directors and executive officers.
Key Figures
Shares purchased: 6,250 shares of common stock
Purchase price per share: $1.60 per share
Shares owned after transaction: 38,750 shares of common stock
+1 more
4 metrics
Shares purchased
6,250 shares of common stock
Purchased by director Eric Chin on August 26, 2026 in private placement
Purchase price per share
$1.60 per share
Price paid in the August 26, 2026 private placement transaction
Shares owned after transaction
38,750 shares of common stock
Direct holdings of Eric Chin following the reported purchase
Net buy shares in filing
6,250 shares
Net buy direction across all reported transactions in this Form 4
Key Terms
private placement, Securities Purchase Agreement, institutional investors
3 terms
private placement financial
"acquired 6,250 shares ... in private placement by the Issuer"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Securities Purchase Agreement financial
"pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
institutional investors financial
"by and among certain institutional and individual investors identified"
Institutional investors are large organizations, like pension funds, insurance companies, and mutual funds, that invest huge amounts of money on behalf of many people. Their decisions can influence the economy because they buy and sell big chunks of stocks, bonds, or other assets. They matter because their actions can affect market prices and trends.
FAQ
What insider transaction did Eric Chin report in BMRA stock?
Eric Chin reported a purchase of Biomerica (BMRA) common stock. On August 26, 2026, he acquired 6,250 shares at a price of $1.60 per share in a private placement conducted by Biomerica.
Was Eric Chin’s BMRA stock purchase part of a private placement?
Yes. The filing states that on August 26, 2026, Eric Chin acquired 6,250 shares of Biomerica common stock in a private placement by the issuer under a Securities Purchase Agreement dated August 20, 2026.
Who participated alongside Eric Chin in the Biomerica private placement?
The Securities Purchase Agreement lists certain institutional and individual investors, including among others B. Riley Principal Capital, LLC and certain members of Biomerica’s Board of Directors and executive officers, as parties to the private placement.
Was Eric Chin’s BMRA trade under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote indicating that the August 26, 2026 purchase was made pursuant to a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
